ReedSDCramerSCBloughDKMeyerKJarvikJG.Treatment with tissue plasminogen activator and inpatient mortality rates for patients with ischemic stroke treated in community hospitals. Stroke2001;32: 1832–40.
2.
YrjänheikkiJTikkaTKeinänenRGoldsteinsGChanPHKoistinahoJ.A tetracycline derivative, minocycline reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci USA1999;96:13496–500. www.pnas.org/cgi/reprint/96/23/13496.pdf (accessed 2004 Aug 12).
3.
XuLFaganSCWallerJLEdwardsDBorlonganCVZhengJLow-dose intravenous minocycline is neuroprotective after middle cerebral artery occlusion-reperfusion in rats. BMC Neurol2004;4:7. DOI 10.1186/1471-2377-4-7.
4.
WangCXYangTNoorRShuaibA.Delayed minocycline but not delayed mild hypothermia protects against embolic stroke. BMC Neurol2002;2:2. DOI 10.1186/1471-2377-2-2.
5.
LeTM.Minocycline: Neuroprotective mechanisms in Parkinson's disease. Curr Pharm Des2004;10: 679–86.
6.
ColucciMScopeceSGelatoAVDimonteDSemeraroN.In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis—study in healthy subjects and correlation with blood fibrinolytic parameters. Thromb Haemost1997;77: 725–9.
7.
KanbbRMChiuATReillyTM.Effects of recombinant plasminogen activator inhibitor type 1 on fibrinolysis in vitro and in vivo. Thromb Res1990;59: 309–17.
8.
KleinNCCunhaBA.Tetracyclines. Med Clin North Am1995;79: 789–801.
